Gunderson Dettmer represented client AtaCor Medical, a medical device company, in its $28 million Series C financing led by Arboretum Ventures. AtaCor is transforming cardiac pacing and defibrillation lead technology with its proprietary extravascular cardiac rhythm management system that provides the full benefits of traditional, transvenous implantable cardiac defibrillation and temporary pacing without placing leads or devices in the heart or vascular system.

The new capital, which will be used to support FDA submission for its extravascular temporary pacing lead system as well as completion of a pilot study for the third generation EV-ICD lead system, included participation from Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures and BayMed Venture Partners.

In the announcement of the transaction, AtaCor Medical CEO Rick Sanghera said, "We welcome the Arboretum team to AtaCor and look forward to having Jan's expertise and guidance in the boardroom. As we plan for our upcoming clinical and regulatory milestones, this investment supports efforts that will bring AtaCor's novel products to patients."

The Gunderson Dettmer deal team was led by Ilan Lovinsky and Jonathan Spencer and included Matthew Rietfors and Benjamin Cohen-Kurzrock.

Companies
AtaCor Medical 
Arboretum Ventures